Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans.

Abstract

We report an 81-year-old man with arteriosclerosis obliterans with sharp rest pain of the left lower leg below the knee that was resistant to conventional drug therapy. Gene therapy using hepatocyte growth factor (HGF) was performed, following which the symptoms remarkably improved. Magnetic resonance (MR) angiography did not detect any development of collateral vessels following gene therapy; however, technetium-99m-methoxyisobutylisonitrile (Tc-99m)-MIBI scintigraphy revealed the development of micro-circulation in the lower leg following HGF gene therapy. This is the first report on the usefulness of Tc-99m-MIBI scintigraphy to evaluate the effectiveness of HGF gene therapy for peripheral arteriosclerosis obliterans.

• Authors: Takuji Yamagami, Keiichi Kanda, Chio Okuyama, Tsunehiko Nishimura
• Journal: Annals of nuclear medicine (Ann Nucl Med) Vol. 23 Issue 2 Pg. 205-8 (Feb 2009) ISSN: 0914-7187 [Print] Japan
• PMID: 19225945 (Publication Type: Case Reports, Journal Article)

Chemical References

• Radiopharmaceuticals
• Hepatocyte Growth Factor
• Technetium Tc 99m Sestamibi

Topics

• Aged, 80 and over
• Atherosclerosis (diagnostic imaging, genetics, therapy)
• Genetic Therapy (methods)
• Hepatocyte Growth Factor (genetics, therapeutic use)
• Humans
• Leg (blood supply)
• Male
• Peripheral Vascular Diseases (diagnostic imaging, genetics, therapy)
• Radionuclide Imaging
• Radiopharmaceuticals
• Technetium Tc 99m Sestamibi
• Treatment Outcome